In addition to these clinical trials, it would be of significance to test the efficacy of CXCR3 antagonists in COVID-19 patients, considering that systemic CXCL10 levels are positively correlated with the severity of the disease (Huang et al., 2020a; Chi et al., 2020). This evidence concerns the gene CXCL10 and COVID-19.